ResearcherWashington University in St. LouisNo recent work listed

Kathryn Jane Fowler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9188-1701; OpenAlex author ID A5038164406. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper

Papers 2

CT Assessment of Pancreatic Cancer: What Are the Gaps in Predicting Surgical Outcomes? Co-author DOI 10.1148/radiol.2018181912 ↗
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

David C. Linehan · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
William G. Hawkins · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Timothy M. Nywening · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Dominic E. Sanford · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Roheena Z. Panni · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Steven M. Strasberg · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Adetunji T. Toriola · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Benjamin R. Tan · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Kian‐Huat Lim · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Albert Craig Lockhart · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Ryan C Fields · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
Andrea Wang‐Gillam · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗
David G DeNardo · 1 shared paper, 2016 · strength 0.04
- Paper Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline… DOI 10.1016/s1470-2045(16)00078-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.